Patients don’t behave the way they used to. They’re not just turning up for appointments and following instructions. They’re researching symptoms at 2 am, sense-checking decisions in niche patient forums, and watching other patients talk about their experiences on TikTok, YouTube, and Reddit. They are openly comparing treatments, questioning symptoms, and forming expectations long before they sit down with a clinician.
And yet, if you step back and look at how we approach researching patients, it can take on a very different reality. One where patients are more passive, less connected, and easier to fit neatly into a research design.
Our recent conversations with industry colleagues and clients suggest that the gap is starting to show.
We know that patients today are more informed, more connected, and far more vocal than they were even five years ago. As Carly Welsh (Beyond Blue) put it in our recent webinar.
“Patients are more educated, more engaged, and more digitally connected than at any point in the past… they’re researching, comparing experiences, and sharing their own stories.”
We’ve been seeing the same shift in our Power of Words work. The way patients talk about conditions and treatments is changing as healthcare and pharma drifts ever more into mainstream media. Expectations have shifted. People want clarity, relevance, and a sense of control. Language doesn’t just describe the experience, it actively shapes and dictates it. There is a whole new lexicon building in the healthcare world that goes way beyond the clinical and the rational.
That shift came through strongly at the recent BHBIA conference, too. The growing influence of non-clinical voices, the shifting trust in pharma, and the consumerization of healthcare are no longer emerging trends, they are here to stay and grow.
Patients are not passive recipients in a care pathway; they are fundamentally shaping how it’s understood.
Patient research like it’s 2015
But much of our research still assumes otherwise. We lean on HCPs to interpret patient needs. We design studies that prioritize efficiency over realism. We default to structured questioning and assume it will surface what matters.
Barbara Hinzmann (Bayer) captured the tension well in our patient research-dedicated webinar:
“Ultimately, yes, physicians make the decisions… but whether a treatment is started, taken correctly, and continued – that’s driven by the patient.”
That gap between decision and behavior is where patient insight matters most, and still it’s often where it’s missing.
You see it most clearly when you look at how research is designed.
For example, in our discussions, we heard anecdotally about a Parkinson’s study that asked patients to stay within a fixed video frame, about surveys that were not compatible with screen readers, and about long sessions for people managing fatigue, pain, or breathlessness.
One patient put it simply: “I’m totally blind… if there is no way to make this work with a screen reader, I won’t be able to take part.”
These aren’t extreme cases, they’re entirely predictable realities of the populations we’re trying to understand.
As Tamara Burke (Konovo) reflected: “You have to take a step back and look at the patient, what they can realistically do.”
Patients aren’t a standard consumer audience; they’re navigating fluctuating symptoms, emotional pressure, and practical constraints. When research doesn’t accommodate that, it doesn’t just lower engagement; it changes who gets heard. It might be the most important voices that are being missed, and, of course, that has a direct impact on the quality of the insight.
The irony is that patients themselves are not the barrier.
If anything, the opposite.
“People want to share their stories”, as Pam Cusick (Rare Patient Voice) put it. “They’re incredibly open when given the opportunity.”
Wes Michael (Rare Patient Voice) echoed the same point: “Patients want to tell their stories… and once you find one, they often help you find others.”
There is a willingness, even an eagerness, to participate. But that doesn’t mean we can take that eagerness for granted – it only works if we meet them halfway.
At the same time, patients are already telling us what we’re missing.
Across TikTok, forums, and social platforms, people are sharing what it’s really like to live with a condition, not just clinically, but practically and emotionally.
“It’s not just the condition”, one patient explained. “It’s everything around it… what you plan, what you avoid. You just learn to work around it.”
Another reflected on diagnosis: “I didn’t really hear anything after that [the diagnosis]… I just heard the name.”
That moment, where clinical language lands emotionally, and everything else gets lost is incredibly important.
As Carly Welsh (Beyond Blue) highlighted, “one phrase can completely shape how patients interpret everything that follows.”
As we know, the real insight sits not in what is said, but in what is not said and what it means. And that matters more now, because the stakes have changed. Patient insight is not about adding ‘color’ – it directly influences trial design, adherence, positioning and ultimately whether a treatment works in the real world.
Barbara Hinzmann (Bayer) was clear on this: “A prescribed treatment that isn’t tolerated or adhered to is a failure in the real world.”
And, in increasingly crowded markets, patient experience is often the only meaningful differentiator left.
“Market share is decided after the prescription.”
Despite that, patient research is still often brought in too late.
After strategy is defined, after materials are developed, after key assumptions are already locked in.
From a fieldwork perspective, this is a familiar frustration.
“We’re often the last stop”, Pam said. “And then it’s ‘we need patients in a few days’.”
At that point, patient insight can only do so much. It validates and refines, but it struggles to shape what has already been molded.
As Paula Coyle (Beyond Blue) pointed out, making the patient voice central isn’t the challenge in theory. The challenge is making it work in practice, especially when it’s difficult.
“The patient voice can get deprioritized… just because it’s too difficult. But that’s exactly when it matters most.”
That’s particularly true in rare diseases, where populations are small and harder to access, but the consequences of misunderstanding them are magnified. However rare diseases is the area where we are seeing the biggest R&D and hence the biggest research need.
So what does it look like when research catches up?
It starts earlier, before the direction is set. It’s designed around real lives rather than ideal scenarios. It recognizes that some of the richest insight already exists in how patients naturally express themselves, not just in how they answer structured questions.
And it goes deeper. Not just what patients think, but how they live their lives. How decisions evolve over time, and where small frictions build into bigger barriers.
As Carly put it, “Patients remind us that nuance matters.”
And it’s that nuance, often messy, sometimes contradictory, where the real value sits.
It is clear that the healthcare landscape is rapidly becoming more complex, more fragmented, and faster-moving.
Patient behavior is part of that shift, and naturally so is the role of insight, to make sense of data, connect it, and use it to shape better decisions. If we want insight that holds up in the real world, we have to start designing for the real world.
Patients are more educated, connected, and vocal than ever: researching, comparing experiences, and shaping expectations long before they reach a clinic.
But much patient research still assumes a more passive world, prioritizing efficiency over realism, which changes who gets heard and what insights you end up with.
To keep pace, research needs to start earlier, be grounded in real lives, and take patient language seriously – because adherence, differentiation, and real‑world outcomes are determined after the prescription.
If you’d like to continue the discussion, reach out to our team, they’re always up to talk about patient research.